Related Experiment Video
Updated: Aug 5, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review
Klarisse Man Ling Neo1, Alicia Le How2, Asher Yu Han Ang2
1Faculty of Medicine and Health, UNSW Sydney, Kensington, Australia.
Background And Aim:
Given the prevalence and chronicity of irritable bowel syndrome (IBS), this systematic review aimed to synthesize evidence on the cost of illness of IBS, with attention to the relative contributions of direct healthcare and indirect non-healthcare costs.
Methods:
A systematic search of PubMed, Embase, and the Cochrane Library was conducted from inception to August 2025, following PRISMA 2020 guidelines (PROSPERO CRD420251266432). Studies were included if they primarily assessed costs of IBS with sufficiently detailed methodology. Costs were inflation-adjusted to 2024 US dollars using World Bank consumer price indices and prevailing exchange rates. Risk of bias was assessed using the Consensus on Health Economic Criteria (CHEC) list.
Results:
Thirty-three studies met our inclusion criteria, spanning 14 countries from 1992 to 2022. Mean annual direct healthcare costs per patient ranged widely, from US$193 in Korea to US$31113 in the United States among patients with IBS-C. Among the 10 studies adopting a societal perspective, indirect costs such as absenteeism, presenteeism, and lost productivity frequently constituted a dominant share of total costs. In some settings, non-healthcare costs exceeded direct healthcare costs several-fold (e.g., Sweden: US$17112 vs. US$1943 for IBS-C). Treatment failure and inadequate symptom control were associated with higher expenditures. IBS-C incurred the highest subtype-specific costs, and racial and gender disparities in spending were identified.
Conclusions:
IBS imposes a considerable global economic burden. When societal perspectives are adopted, indirect costs emerge as a predominant driver of total costs, necessitating holistic management strategies. Importantly, assessments limited to direct healthcare expenditures underestimate the true economic impact of IBS.
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:23Irritable Bowel Syndrome
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...